BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase I (World)
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 7/28/2014
Bavarian Nordic (BAVA.CO) Announces First Patient Treated In A Phase 1 Study Of MVA-BN® Brachyury In Advanced Cancer 7/24/2014
Tekmira Pharmaceuticals Corporation (TKMR) Provides Update on TKM-Ebola Phase I Clinical Hold 7/21/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014
Can-Fite BioPharma (CFBI) CEO To Deliver Scientific Presentation And Serve On Expert Panel At Purines 2014 In Bonn, Germany On July 23-27, 2014 7/21/2014
BioLineRx Ltd. Announces Results From Phase 1/2 Study For Celiac Treatment 7/16/2014
Novartis AG (NVS) To Test Alzheimer's Drugs In Patients Without Symptoms 7/15/2014
Probiodrug AG Presents Development Overview Of PQ912, Probiodrug’s QC-Inhibitor For Alzheimer’s Disease 7/10/2014
Novartis AG (NVS) Wins Breakthrough Status For New Leukemia Treatment CTL019 7/8/2014
Glenmark Pharmaceuticals's Novel Monoclonal Antibody GBR 830 For Treatment Of Autoimmune Diseases Entering Human Trials 7/3/2014
Tekmira Pharmaceuticals Corporation (TKMR) Sinks As The FDA Puts Ebola Study On Hold; Stock Down -15.54% At Market Close (July 3, 2014) 7/3/2014
GlycoVaxyn AG Announces The Initiation Of A Phase I Clinical Trial In Collaboration With Janssen Pharmaceutical Inc. For A Vaccine Against Extra-Intestinal Pathogenic Escherichia Coli Causing Urinary Tract Infection 7/1/2014
Hanmi Pharmaceutical, Co., Ltd And Collaborative Partner Kinex Pharmaceuticals Report Encouraging Results On Oraxol® For Patients With Advanced Gastric Cancer From A Phase I/II Clinical Study 6/30/2014
Bone Therapeutics Starts Patient Treatment In First Ever Clinical Trial With Allogeneic Bone Cell Therapy Product 6/25/2014
Debiopharm Announces Initiation Of A Phase I Study Of Debio 1450, An IV/Oral Potent Antibiotic Active Against Staphylococcal Infections 6/19/2014
Senhwa Biosciences Initiates Phase 1/2 Trial Of CX-4945 In Combination With Gemcitabine And Cisplatin 6/17/2014
Basilea Pharmaceutica (BSLN.SW) Initiates Phase 1 Combination Study With Its Gram-Negative Antibiotic BAL30072 And Meropenem 6/12/2014
InnFocus Highlights Clinical Results At The European Glaucoma Society Congress 6/11/2014
D-Pharm Ltd.'s Anti-Epileptic Drug DP-VPA Is Granted Fast Track Status By The Chinese Food And Drug Administration (CFDA) 6/9/2014
Medgenics, Inc. Announces First Patient Implanted In Phase 1/2 Clinical Trial Of MDGN-201 (EPODURE) 6/6/2014
AstraZeneca PLC (AZN) Shows Off Its Cancer Pipeline 6/4/2014
Basilea Pharmaceutica (BSLN.SW)'s Oncology Drug Candidate BAL101553 Shows First Evidence Of Antitumor Activity In Phase 1 Study 6/2/2014
Nanobiotix Presents Successful Phase I Results For Its Lead Nanomedicine Product NBTXR3 At American Society of Clinical Oncology 6/2/2014
Scancell: Update On Phase 1/2 Clinical Trial Of SCIB1 In Stage III/IV Melanoma 6/2/2014
Dilaforette Presents Results From Exploratory Phase 1/2 Clinical Trial In Uncomplicated Malaria 5/30/2014
Benitec Limited (BLT.AX) Commences Patient Dosing With TT-034 In Patients With Hepatitis C 5/29/2014
uniQure Announces Successful Transfection Of Liver Cells With AAV5 And Strong Safety Data From Acute Intermittent Porphyria Clinical Trial 5/27/2014
Propanc Health Group Targets Cancer Patient Trials in 2015 5/19/2014
AstraZeneca PLC (AZN) Cancer Drug Coveted By Pfizer Inc. (PFE) Works In Trial 5/16/2014
Oncos Therapeutics Ltd. Demonstrates Systemic, Tumor-Specific Immune Response by Local Administration of its Lead Product ONCOS-102 5/8/2014
Xspray Microparticles AB Announces Positive Phase I Data for HyNap™ Nilotinib 5/8/2014
Covagen Initiates Phase 1b/2a Study Of Bispecific Anti-TNF/IL-17A Fynomab COVA322 5/5/2014
Promising Results In Phase 1 Trial Lead immatics biotechnologies GmbH To Continue Work On Vaccine (IMA950) For Glioblastoma 4/23/2014
Aspireo Pharmaceuticals Reports Data In Further Phase Ib Study 4/22/2014
One Of A Kind Trial To Test 14 AstraZeneca PLC (AZN), Pfizer Inc. (PFE) Drugs At The Same Time 4/18/2014
Critical Pharmaceuticals Limited, The University of Nottingham And Nottingham University Hospitals NHS Trust Starts First Phase I Clinical Trial On A Nano-Enabled Intranasal Teriparatide For The Treatment Of Osteoporosis 4/15/2014
Vectura Group plc (VEC.L): FAVOLIR Regulatory Update 4/11/2014
Prothena Corporation plc Release: First Human Dosed In Phase 1 Study Of PRX002 For Treatment Of Parkinson's Disease 4/9/2014
Newron Pharmaceuticals (NWRN) Release: New Results With NW-3509 Presented At SIRS Conference 4/8/2014
Oxford BioMedica PLC (OXB.L) Completes Patient Recruitment Into Retinostat® Phase I Trial 4/7/2014
Novartis AG (NVS) Shows Off A Strong Pipeline Of 19 New Compounds At American Association for Cancer Research 4/4/2014
Kamada Ltd. (KMDA.TA) Announces U.S. Proof-Of-Concept Study With Glassia® For Graft-Versus-Host Disease 4/3/2014
Novaliq GmbH Announces Launch Of A Phase 1 Study Following US And European Patent Approval Of Cyclasol® (Cyclosporin) Eye Drops 4/3/2014
Innate Pharma (IPH.PA ) : Start Of Cohort Expansion Of Phase I Trial With Lirilumab And Nivolumab In Selected Solid Tumors 3/31/2014
e-Therapeutics plc Reports Positive Interim Results From UK Phase Ia Trial Of ETS2101 (Dexanabinol) In A Variety Of Solid Tumours 3/31/2014
Ability Pharmaceuticals Initiates Clinical Trial With Its Dual mTORC1/C2 Inhibitor ABTL0812 In Patients With Lung And Pancreatic Cancer 3/26/2014
Scancell: 8mg Higher Dose SCIB1 Study On Track 3/21/2014
Adocia Confirms Positive Clinical Results For Its Biochaperone® Combo, A Combination Of Long-Acting Insulin Glargine And Fast-Acting Insulin Lispro 3/20/2014
Hua Medicine Reports Strong Results For Early Diabetes Drug Trial 3/20/2014
GW Pharmaceuticals Provides Update on Cannabinoid Pipeline 3/17/2014
Betagenon AB: First Time In Man-AMPK Activator O304 3/10/2014
Adocia Announces Preliminary Positive Clinical Results For Its Combination Of Long-Acting Insulin Glargine And Fast-Acting Insulin Analog Lispro, Biochaperone® Combo 2/27/2014
GANYMED Pharmaceuticals AG's IMAB027 Enters Phase I/II Clinical Trial For Ovarian Cancer 2/12/2014
Nanobiotix: Sees Clinical Advance In Soft Tissue Sarcoma Pilot Trial With Lead Product, NBTXR3 Market Development Plan Outlined For Earlier Potential Launch In 2016 2/11/2014
THERAVECTYS Finalizes The Recruitment Of Patients For The Phase I/II Clinical Trial Of Its Anti-HIV Therapeutic Vaccine Candidate 2/5/2014
Bionomics Limited (BMICY.PK) Release: BNC105 Phase I/II Trial Achieves A High Response Rate In Ovarian Cancer 2/3/2014
Admedus Herpes Interim Phase I Results 2/3/2014
Orion Corporation Release: The Androgen Receptor Inhibitor ODM-201 - New Insights In The Treatment Of Prostate Cancer 2/3/2014
e-Therapeutics plc Temporary Halts Recruitment Into ETS2101 Cancer Trials 1/24/2014
Pluristem Therapeutics (PSTI)' Phase I/II Muscle Injury Trial Successfully Meets Primary Safety & Efficacy Endpoints 1/21/2014
Faron Pharmaceuticals Release: Promising New Treatment For Life Threatening Acute Respiratory Distress Syndrome (ARDS) 1/15/2014
Oxford BioMedica PLC (OXB.L) Announces Publication Of ProSavin® Phase I/II Study in The Lancet 1/10/2014
BrainStorm Cell Therapeutics Inc. Says Stem Cells Helped 75-Year Old Patient With ALS And MG 1/7/2014
Results Of Pluristem Therapeutics (PSTI)'s Phase 1/2 Muscle Injury Trial To Be Announced On January 21, 2014 1/6/2014
ARTES Biotechnology Release: TA101 GOCLIN European Funded Project For The Development Of An Innovative Product For The Treatment Of Rheumatoid Arthritis – 1,7M€ Total Budget 12/23/2013
Blaze Bioscience Inc. Announces Initiation Of First-In-Human Phase 1 Clinical Study Of BLZ-100 12/19/2013
BeiGene Co.,Ltd Enrolls First Patient In Phase 1 Study Of BGB-283 12/19/2013
BioLineRx Ltd. Enters Clinic With Novel Treatment For Celiac Disease 12/19/2013
BerGenBio AS Release: Data Highlights BGB324 As A Potential Novel Treatment Option For Drug Resistant Chronic Myeloid Leukemia 12/17/2013
Drawbridge Pharmaceuticals Initiates Clinical Trial For Phaxan™ 12/16/2013
CureVac GmbH Completes Patient Recruitment For Phase 2 Clinical Trial Of Mrna-Based Prostate Cancer Treatment 12/16/2013
MorphoSys AG Announces Additional Clinical Trial of MOR208 12/10/2013
Adaptimmune Ltd. Announces Interim Results From A Phase I/II Trial Of Engineered T Cells Targeting Cancer Testis Antigens In Multiple Myeloma 12/10/2013
Summit Corporation Announces First Patient Dosed In A Phase 1b Clinical Trial Of Smt C1100 For Treatment Of Duchenne Muscular Dystrophy 12/9/2013
Rhizen Pharmaceuticals S.A. Announces Initiation Of A "First In Human" Phase-1 Trial Of RP6530, A Dual PI3K Delta/Gamma Inhibitor, In Patients With Hematological Malignancies 12/6/2013
Anti-Cancer Program Originating From Lead Discovery Center Reaches Clinical Trials 12/5/2013
Galapagos NV (GLPG.BR) Reports Positive Phase 1 Results For GLPG1205 12/4/2013
VBL Therapeutics Receives FDA Fast Track Designation For Lead Compound VB-111 11/27/2013
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1 Study Of ISIS-GSK3 Rx And Earns $3 Million Milestone Payment From GlaxoSmithKline (GSK) 11/26/2013
Living Cell Technologies Ltd. Release: NTCELL Clinical Trial: Recruitment Of Further Patients Approved 11/25/2013
TopoTarget A/S Release: Final Results From CLN-14 Study In STS 11/20/2013
BioLineRx Ltd. Reports Publication In Peer Review Journal Of Positive Phase 1/2 Results In Stem Cell Mobilization For Multiple Myeloma 11/19/2013
Adocia Announces The Initiation Of A Clinical Trial On Its Combination Of The Long-Acting Insulin Glargine And A Fast-Acting Insulin Analog 11/13/2013
PROMETHERA Biosciences S.A./N.V. Successfully Enrols Twenty Patients In Its Multicentric Phase I/II Trial 11/12/2013
Gentium S.p.A. Announces Successful Completion Of Defibrotide Phase 1 Study In Japan 11/12/2013
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM) -Study Features THC and CBD as the Primary Cannabinoids 11/11/2013
FDA Grants Orphan Drug Status for PAT-SM6 11/6/2013
Swedish Orphan Biovitrum Hosts Capital Market Day Event - Announces Phase I Complement Inhibitor Programs 11/5/2013
Canbex Therapeutics Commences Phase I Clinical Trial of Lead Product VSN16R as a Potential Treatment for Spasticity in Multiple Sclerosis 11/4/2013
SEEK Announces Publication of HIV-v Data in Vaccine Journal 11/1/2013
CEVEC Pharma Release: Completion of a "First in Human" Clinical Phase I Study With a Therapeutic Protein Derived From CAP® Cells 11/1/2013
New Two-Hormone Roche (RHHBY) Drug Shows Promise in Diabetes, Obesity 11/1/2013
Kamada Ltd. (KMDA.TA) Reports New Data From an Extension Study of Its Phase I/II Trial With Glassia in Pediatric Patients With Type 1 Diabetes 10/31/2013
ISA Pharmaceuticals Initiates Phase I/II Clinical Trial With ISA101 in Women With Cervical Cancer 10/29/2013
Clovis Oncology (CLVS)'s CO-1686 Continues to Demonstrate Promising Clinical Activity and Safety in Updated Phase I Study Results 10/28/2013
Immunicum Doses the First Patient in a New Clinical Phase I/II-Study in Primary Liver Cancer 10/23/2013
Galapagos NV (GLPG.BR) Presents Superior Potentiator Series for CF 10/17/2013
Oxford BioMedica PLC (OXB.L) Receives Agreement From FDA and ANSM to Resume Recruitment Into Ocular Clinical Trials 10/17/2013
Galapagos NV (GLPG.BR) to Present Phase 1 Data on FFA2 Antagonist GLPG0974 at UEG Week in Berlin 10/16/2013
Protalix Biotherapeutics, Inc. (PLX) Announces Positive Phase I Clinical Trial Results for Oral GCD in Gaucher Disease Patients 10/14/2013
Sihuan Pharmaceutical Holdings Group Ltd. Approved for China Trials of Innovative Cancer Drug 10/11/2013
Karolinska Development AB: Pergamum Announces Final Data From Phase I/II Study of LL-37 in Patients With Chronic Leg Ulcers 10/10/2013
Medivir AB (MVIRb.F) Release: Positive Results From a Phase I Study With MIV-711 for the Treatment of Osteoarthritis and Other Bone Related Disorders 10/9/2013
Scancell Release: Investor Update Showcases Moditope® Platform and Updates SCIB1 Trial Progress 10/1/2013
Tesaro, Inc. Describes Initial Phase 1 Clinical Data for TSR-011 Presented at the European Cancer Congress 2013 9/30/2013
BerGenBio AS Study Published in Blood Highlights Axl Inhibition as a Novel Therapeutic Approach for Acute Myeloid Leukemia 9/30/2013
Ariad Pharmaceuticals, Inc. (ARIA) Presents Updated Phase 1/2 Data on AP26113 in Patients With Non-Small Cell Lung Cancer 9/30/2013
To-BBB technologies BV Presents Clinical Data on Lead Product 2B3-101 9/26/2013
Living Cell Technologies Ltd. Release: First-in-Man' Implant of Regenerative Cell Therapy in Parkinson's Disease 9/24/2013
Versartis, Inc. Presents Latest Positive Results From Its Pediatric Study of Long-Acting Growth Hormone Treatment at International Endocrinology Conference 9/23/2013
Skyepharma PLC (SKYEF) Release: Flutiform Trial for COPD Initiated in Europe 9/19/2013
ISA Pharmaceuticals Initiates Phase I/II Clinical Trial of ISA101 in Patients With Anal Intraepithelial Neoplasia (AIN) 9/16/2013
Wanbang Biopharmaceuticals to Begin Clinical Trial of Fast-Acting Insulin Analogue 9/16/2013
Patrys Limited (PAB.AX) Release: PAT-SM6 Receives Orphan Drug Designation for Multiple Myeloma in Europe 9/12/2013
Dompe Announces the FDA Has Granted Orphan Drug Designation to Its rhNGF-Based Treatment for Retinitis Pigmentosa 9/11/2013
Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT 9/10/2013
Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors 9/9/2013
Gamida Cell Ltd. Announces the Successful Transplantation of the First Patient in the Company's Phase I/II Study of NiCord® in a Single Cord Configuration 9/9/2013
ProSensa Holding N.V. Initiates First Patient Dosing in Phase I/II trial of PRO053 9/6/2013
Hua Medicine Begins Phase I Trial of Novel Diabetes Treatment 9/6/2013
Apitope Announces Positive Results From Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis 9/3/2013
Imaxio Announces the First Human Clinical Trial Using Its Pro-Immunogenic Technology IMX313 in Tuberculosis 9/3/2013
Congenia Announces Enrollment of First Healthy Volunteer in Phase 1 Clinical Trial of GNX-5086 8/27/2013
Karolinska Development AB: Lipidor Reports Positive Clinical Phase I/II Data in Psoriasis 8/27/2013
Lipidor Reports Positive Clinical Phase I/II Data in Psoriasis 8/27/2013
Oncolytic Virus Specialist Virttu Biologics Confirms Treatment of First Cohort of Patients in Phase I/II SEPREHVIR® Study in Mesothelioma 8/26/2013
Patrys Limited (PAB.AX) Release: Data From 2nd and 3rd Cohorts of Patients in Multiple Myeloma Clinical Trial 8/13/2013
Trophos Completes Patient Enrolment in a First Study of Olesoxime in Relapsing Remitting Multiple Sclerosis 8/7/2013
Patrys Limited (PAB.AX)'s Multiple Myeloma Clinical Trial to Progress to Final Patient Group 8/7/2013
AllaChem Announces the Beginning of Phase I Clinical Studies of AV4025, a Potent Small Molecule for the Treatment of Chronic Hepatitis C Infection 8/5/2013
Boehringer Ingelheim Corporation Release: First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for linagliptin in Type 2 Diabetes 7/31/2013
uniQure Announces Start of Parkinson's Disease Gene Therapy Phase I Trial by University of California, San Francisco (UCSF)/National Institutes of Health (NIH) to Test Its GDNF Gene in Patients 7/29/2013
PRANA Biotechnology (PRAN) Doses First Patient in PBT2 Alzheimer's Extension Study 7/29/2013
Patrys Limited (PAB.AX) Completes Treatment of Third Patient Group in Multiple Myeloma Trial 7/25/2013
Adaptimmune Ltd. Announces Opening of Phase I/IIa Clinical Trial in Ovarian Cancer 7/25/2013
Immunicum AB Release: The Medical Products Agency Clears Unique Swedish Cancer Vaccine for Clinical Tests in Liver Cancer Patients 7/22/2013
TopoTarget A/S Release: Belinostat Gets European Orphan Drug Designation for the Treatment of Malignant Thymomas 7/18/2013
Alize Pharma Launches the First Phase I Clinical Trial for AZP-531, Its Unacylated Ghrelin Analog, in Type 2 Diabetes 7/16/2013
Probiodrug AG Provides Update on Clinical Development of PQ912, Its Most Advanced QC-Inhibitor for Alzheimer's Disease 7/16/2013
Vernalis PLC (VNLPY.PK) Initiates Phase Ib/II POC Study of V81444 7/12/2013
Scancell SCIB1 8mg Study Update 7/12/2013
Pluristem Therapeutics (PSTI) Completes Enrollment for Phase I/II Muscle Injury Trial 7/11/2013
Ablynx Starts Additional Phase I Studies With Anti-RSV Nanobody ALX-0171 7/8/2013
Immunomedics, Inc. (IMMU) Reports First Results From Phase Ib Study of 90Y-Clivatuzumab in Patients With Metastatic Pancreatic Cancer After 2 or More Prior Therapies 7/3/2013
CLL Pharma and Leurquin-Mediolanum Announce Initiation of Phase 1b Clinical Trial of the Compound Syn1002 in Pain 7/2/2013
GlaxoSmithKline (GSK) Muscular Dystrophy Drug Gets "Breakthrough" Status 6/28/2013
Edge Therapeutics Reports Positive Early Clinical Experience With EG-1962 to Prevent Serious Complications After Brain Hemorrhage 6/27/2013
Mirna Therapeutics, Inc. and Horizon Discovery Ltd. Publication Elucidates Novel miR-34 Tumor Suppressor Pathway, Underscores miR-34 as Important Anticancer Approach 6/26/2013
Verona Pharma Release: First Patient Dosed in Clinical Trial to Further Evaluate Efficacy of VRP700 as a Treatment for Chronic Severe Cough 6/24/2013
Affimed Therapeutics AG Reports Phase 1 Clinical Data for Its Immunotherapy AFM13 in Relapsing/Refractory Hodgkin Lymphoma Patients 6/24/2013
Ablynx' Partner Initiates a Phase I Study and Doses First Healthy Volunteer With ALX-0761 6/21/2013
BerGenBio AS Announces Initiation of Phase I Clinical Trial for First-in-Class AXL Receptor Tyrosine Kinase Inhibitor BGB324 to Treat Aggressive and Metastatic Cancers 6/20/2013
Allied's Herpes Vaccine Progresses to Phase 1 Clinical Trial 6/19/2013
Vaxil Reports Promising Results From Its Follow-Up Clinical Trial of ImMucin in Multiple Myeloma a Patients 6/18/2013
As the First Biopharmaceutical Company Worldwide, Apceth GmbH Receives Approval for a Clinical Trial With Genetically Modified Adult Mesenchymal Stem Cells for the Treatment of Cancer 6/13/2013
Nanobiotix Receives Approval From ANSM to Start New Clinical Trial With Lead Product NBTXR3 6/13/2013
Imperial Innovations Release: Autifony Initiates Phase I Trial for Treatment of Hearing Loss and Tinnitus 6/4/2013
Nanobiotix' NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma 6/3/2013
VBL Therapeutics Release: Phase I/II Data of VB-111 Demonstrate Anti-Tumor Effects With Increase in Overall Survival With This Anti-Angiogenic Gene Therapy, in Patients With Recurrent Glioblastoma Multiforme 6/3/2013
TopoTarget A/S Release: Positive Data From the BELIEF trial presented at the 2013 American Society of Clinical Oncology Annual Meeting 6/3/2013
VBL Therapeutics Release: Phase I/II Data of VB-111 Demonstrate Anti-Tumor Effects With Increase in Overall Survival with This Anti-Angiogenic Gene Therapy, in Patients With Recurrent Glioblastoma Multiforme 6/3/2013
Virttu Biologics U.S. Phase I Pediatric Study is Extended to Include Systemic Delivery of Oncolytic Virus 5/31/2013
Ferring Pharmaceuticals Presents Phase III Data for a Controlled Release Misoprostol Vaginal Delivery System for Labour Induction at the First European Congress on Intrapartum Care 5/28/2013
First Patient Dosed in the Phase I/II Study of Umecrine Mood’s Candidate Drug for Premenstrual Dysphoric Disorder 5/23/2013
Medivir AB (MVIRb.F) Release: Positive Results From a Phase Ia Study With MIV-711 for the Treatment of Skeletal Disorders 5/21/2013
Addex Therapeutics (ADXN.SW) Validates Potential Efficacy Biomarker for Phase 1 Trial of Its GABA-B Positive Allosteric Modulator, ADX71441 5/21/2013
Immunicum AB Release: Promising Data for Cancer Vaccine INTUVAX™ in the Treatment of Kidney Cancer 5/20/2013
R-Tech Ueno: Start of the Patient Enrollment of a Phase I/II Clinical Study of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) in U.S. for the Treatment of Severe Dry Eye 5/20/2013
A*STAR and Cytos Biotechnology AG Bring Singapore's First Influenza Vaccine to Clinical Testing 5/17/2013
Successful Phase One Demonstrates Tumor Response With Increased Overall Survival for Lead VBL Therapeutics Compound in Cancer 5/16/2013
Theravalues Release: A Clinical Study Shows the Theracurmin®'s Safety and Potential Role in Improving Quality of Life (QOL) of Pancreatic Cancer Patients 5/10/2013
Patrys Limited (PAB.AX) Release: PAT-SM6 Kills Human Multiple Myeloma Cells 5/8/2013
Imperial Innovations' Cell Medica Treats First Paediatricpatient in Clinical Trial of Cytovir ADV 5/8/2013
Patrys Limited (PAB.AX) Progresses Multiple Myeloma Clinical Trial to Third Patient Group 4/24/2013
Addex Therapeutics (ADXN.SW) Receives Approval to Initiate a Phase 1, First-In-Man, Clinical Study for ADX71441 4/24/2013
Patrys Limited (PAB.AX) Release: New Data Strengthens PAT-SM6 Profile as an Anti-Cancer Treatment 4/22/2013
Karolinska Development AB: Pergamum Announces Last Visit of Last Patient in a Phase I/II Trial of a Potential New Treatment for Hard-to-Heal Wounds 4/19/2013
BioInvent (BOVNF) Release: Preclinical Data Published in Cancer Cell Highlight Novel Antibody BI-505 and Potent Anti-Myeloma Activity 4/16/2013
Genentech (RHHBY)'s Immune Therapy Cancer Drug Shows Promise in Early Study 4/12/2013
Patrys Limited (PAB.AX) Completes Treatment of Second Patient Group in Multiple Myeloma Trial 4/10/2013
SAGE Therapeutics' Refractory Status Epilepticus Program Demonstrates Efficacy in First-in-Man Experience; Case Study to be Highlighted at International SE Meeting 4/4/2013
Protalix Biotherapeutics, Inc. (PLX) Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease 4/2/2013
Agenix Limited to File for Clinical Trial of Hepatitis B Drug by June 4/1/2013
Curie-Cancer Trebles Number of Early Phase Clinical Research Studies With Industry Partners 3/26/2013
Daval International Limited CSO Presents Results From an Exploratory Clinical Trial of AIMSPRO in Amyotrophic Lateral Sclerosis (ALS) at American Academy of Neurology Annual Meeting 3/21/2013
Vince & Associates Clinical Research Sponsors the 14th Annual Phase I & IIa Clinical Trials Conference in London 3/19/2013
Scancell Welcomes New Study in The Journal of Clinical Investigation Suggesting That Melanoma Switches Off the Immune System 3/14/2013
BrainStorm Cell Therapeutics Inc. Presents Breakthrough Phase I/II ALS Clinical Data at the American Academy of Neurology Annual Meeting 3/13/2013
Patrys Limited (PAB.AX) Release: Data From 1st Cohort of Patients in Multiple Myeloma Clinical Trial 3/7/2013
InnaVirVax Announces Presentation of the Results of Its Phase I/IIa Clinical Study at CROI 2013 in Atlanta 3/5/2013
Polyphor Reports Successful Phase I Results for Its Pseudomonas Selective Antibiotic POL7080 3/4/2013
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Hail Results of Dermatitis Study 3/4/2013
PROMETHERA Biosciences S.A./N.V. Opens the French Part of Its Clinical Trial in Cell Therapy 2/28/2013
Quinten Identifies a Combination of Two Synergistic Markers That Predicts a Favorable Response to Treatment in Triple-Negative Breast Cancer 2/25/2013
Gamida Cell Ltd.'s NiCord® Demonstrates Successful Engraftment in Patients With Hematological Malignancies in Phase I/II Study 2/15/2013
Clasado Announces Positive Results of Clinical Study of Bimuno® for Metabolic Syndrome 2/15/2013
Dompe Release: The First Patient Has Been Enrolled in the First International Clinical Trial of rhNGF for the Treatment of Neurotrophic Keratitis 2/14/2013
VAXIMM Study Meets Endpoints in Phase 1/2 2/7/2013
Genethon Receives Approval From the UK Medicine Regulatory Agency to Start a New Clinical Trial for an Inherited Immune Deficiency: Chronic Granulomatous Disease 2/5/2013
OncoEthix Doses First Patient in Its Phase I Trial of OTX015, a BET Bromodomain Inhibitor for the Treatment of Hematologic Malignancies 1/31/2013